Cancer cocktail study halted: early hopes dashed for Triple-Drug combo

NCT ID NCT02959437

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times

Summary

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in people with advanced solid tumors, including lung and colorectal cancers that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, meaning it did not meet its goals or had safety concerns. About 70 people participated, and the main focus was on side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Churchill Hospital

    Oxford, Ox37le, United Kingdom

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Sarah Cannon

    Nashville, Tennessee, 37203, United States

  • The University of Chicago

    Chicago, Illinois, 60637, United States

  • Univ De Navarra

    Pamplona, 31008, Spain

  • University College London Hospitals (Uclh)

    London, W1t7ha, United Kingdom

  • University of California San Diego

    La Jolla, California, 92093, United States

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania, 19014, United States

  • University of Washington

    Seattle, Washington, 98109, United States

  • Vall D Hebron Univ

    Barcelona, 08035, Spain

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.